Grim excavation begins at site believed to contain remains of around 800 babies
"It's a very, very difficult, harrowing story and situation," Irish Prime Minister Micheal Martin said Monday. "We have to wait to see what unfolds now as a result of the excavation."
The former Bon Secours Mother and Baby Home in western Ireland — which closed in 1961 and was run by Catholic nuns — was one of many mother-and-baby homes during the 20th century in the European country. The homes housed unmarried pregnant women as well as tens of thousands of orphans, according to The Associated Press.
Historian Catherine Corless tracked down death certificates in 2014 for nearly 800 children who died at the Bon Secours Mother and Baby Home between the 1920s and 1961. However, she could only find a burial record for one child, the AP reported.
A mass grave was later discovered by investigators in an underground sewage structure at the home. DNA analysis found the structure contained the remains of infants and young children between the ages of 35 weeks gestation and 3 years old, according to the AP.
Family members and survivors will soon have the opportunity to view the works, according to Daniel MacSweeney, who is leading the exhumation of the infant remains.
"This is a unique and incredibly complex excavation," MacSweeney said in a statement.
Any remains recovered from the site will be analyzed and preserved by forensic experts. Identified remains will be returned to family members, while unidentified remains will be buried. The work is expected to take two years to complete, the AP reported.
The sisters who ran the former Bon Secours Mother and Baby Home previously offered a "profound apology," acknowledging they failed to protect the dignity of the women and children that lived there, according to the AP.
In 2021, Prime Minister Martin issued a former state apology after a report found that 9,000 children died in 18 mother-and-baby homes during the 20th century in Ireland.
Daniel MacSweeney and Ireland's National Police and Security Service, An Garda Síochána, did not immediately respond to Fox News Digital's request for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
ADCs Set for Growth Amid Regulatory Evolutions and Technological Advances
The Antibody Drug Conjugates Market presents opportunities in developing novel ADC platforms, expanding into new cancer types, and leveraging biomarker-driven patient selection. Growth is driven by increasing demand for targeted therapies, technological advancements, and investment in R&D despite competition and regulatory challenges. Antibody Drug Conjugates Market Dublin, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates: Market Share, and Growth Analysis by Product Type (Monoclonal Antibodies, Small Molecule Drugs), Application, End User, Technology" report has been added to Antibody Drug Conjugates Market size is valued at USD 11.1 billion in 2025 and is projected to reach USD 42.2 billion by 2033, registering a compound annual growth rate (CAGR) of 18.2% over the forecast period. The Antibody Drug Conjugates (ADCs) Market focuses on the development and commercialization of targeted cancer therapies. ADCs combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, delivering the drug directly to cancer cells while minimizing damage to healthy tissues. The market is driven by the increasing demand for targeted cancer therapies with improved efficacy and safety profiles. The market encompasses various ADC platforms, including linkers, payloads, and conjugation market is segmented based on target antigen, payload, linker, and application. The major target antigens include HER2, CD30, and CD33. The market caters to a diverse range of cancer types, including breast cancer, lymphoma, and leukemia. The market is characterized by intense competition among pharmaceutical and biotechnology companies, with a focus on developing novel ADC platforms and expanding the therapeutic applications of Antibody Drug Conjugates Market is subject to stringent regulatory requirements and evolving guidelines regarding cancer therapies. The market is also influenced by the increasing complexity of cancer biology and the need for highly specific and potent ADCs. The market is expected to continue its growth trajectory, driven by the increasing demand for targeted cancer therapies and the development of innovative ADC Insights: Antibody Drug Conjugates Market Development of novel ADC platforms with improved stability and efficacy. Expansion of ADC applications to solid tumors and other cancer types. Increasing use of biomarker-driven patient selection for ADC therapy. Growing interest in combination therapies involving ADCs and other cancer treatments. Rising adoption of next-generation sequencing and other technologies to optimize ADC development. Increasing prevalence of cancer and the need for effective treatments. Growing demand for targeted cancer therapies with improved safety profiles. Technological advancements in ADC development and conjugation technologies. Rising investment in research and development by pharmaceutical and biotechnology companies. Increasing availability of funding and partnerships for ADC development projects. High cost of ADC development and manufacturing. Complexity of ADC design and optimization. Challenges in delivering the payload to cancer cells and minimizing off-target effects. Evolving regulatory requirements and intellectual property considerations. Competition from alternative cancer therapies, such as immunotherapy and cell therapy What's Included in the Report? Global Antibody Drug Conjugates market size and growth projections, 2024-2034 North America Antibody Drug Conjugates market size and growth forecasts, 2024-2034 (United States, Canada, Mexico) Europe market size and growth forecasts, 2024-2034 (Germany, France, United Kingdom, Italy, Spain) Asia-Pacific Antibody Drug Conjugates market size and growth forecasts, 2024-2034 (China, India, Japan, South Korea, Australia) Middle East Africa Antibody Drug Conjugates market size and growth estimate, 2024-2034 (Middle East, Africa) South and Central America Antibody Drug Conjugates market size and growth outlook, 2024-2034 (Brazil, Argentina, Chile) Antibody Drug Conjugates market size, share and CAGR of key products, applications, and other verticals, 2024-2034 Short- and long-term Antibody Drug Conjugates market trends, drivers, challenges, and opportunities Antibody Drug Conjugates market insights, Porter's Five Forces analysis Profiles of 5 leading companies in the industry - overview, key strategies, financials, product portfolio and SWOT analysis Latest market news and developments Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2025 - 2033 Estimated Market Value (USD) in 2025 $11.1 Billion Forecasted Market Value (USD) by 2033 $42.2 Billion Compound Annual Growth Rate 18.2% Regions Covered Global Antibody Drug Conjugates Market Segmentation By Product Type: Monoclonal Antibodies Small Molecule Drugs By Application: Oncology Autoimmune Diseases Infectious Diseases By End User: Hospitals Specialty Clinics Research Institutes By Technology: Chemical Linkers Bioconjugation Techniques By Distribution Channel: Direct Sales Distributors By Geography: North America (USA, Canada, Mexico) Europe (Germany, UK, France, Spain, Italy, Rest of Europe) Asia-Pacific (China, India, Japan, Australia, Vietnam, Rest of APAC) The Middle East and Africa (Middle East, Africa) South and Central America (Brazil, Argentina, Rest of SCA) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Antibody Drug Conjugates Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Yahoo
Medtronic, Olympus, and CapsoVision Lead with Minimally Invasive and AI-Enhanced Medical Technologies
The 360 Quadrants analysis highlights the leaders in the global Smart Pills market, evaluating over 102 companies. Smart pills, also known as ingestible sensors or digital pills, offer revolutionary diagnostic functions and medication adherence monitoring by transmitting real-time data wirelessly. Key players include Medtronic, Olympus Corporation, and CapsoVision. The market's growth is driven by the demand for less invasive diagnostics and addressing medication non-adherence issues. Challenges include data privacy concerns, high costs, and regulatory complexities. Companies employ strategies like partnerships and tech integration to enhance market presence. Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "Smart Pills Company Evaluation" report has been added to offering. The Smart Pills Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Smart Pills. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and industry trends. 360 Quadrants evaluated over 102 companies, of which the Top 14 Smart Pills Companies were categorized and recognized as quadrant pills, also known as ingestible sensors or digital pills, are revolutionary medical devices designed in the form of a swallowable capsule. Once ingested, these high-tech pills travel through the gastrointestinal (GI) tract to perform diagnostic functions or monitor treatment adherence. Common applications include capsule endoscopy, where a tiny camera captures images of the digestive system, and medication monitoring, where an embedded sensor signals when a pill has been taken. The data is transmitted wirelessly from inside the body to an external receiver, providing clinicians with unprecedented, real-time market for smart pills is primarily driven by the demand for less invasive diagnostic tools. Capsule endoscopy provides a patient-friendly and effective method for examining the small intestine, an area difficult to reach with traditional scopes. Another major driver is the pressing need to solve the multi-billion-dollar problem of medication non-adherence, especially for patients with chronic conditions. By providing objective confirmation that medication has been taken, smart pills can significantly improve disease management and clinical trial data accuracy. Continuous technological advancements are also making these devices more capable and their potential, smart pills face significant challenges. The security and privacy of the sensitive health data they collect and transmit are paramount concerns that must be rigorously addressed. The high cost of the pills and their associated monitoring systems can be a major barrier to widespread clinical use and reimbursement from insurance providers. The regulatory approval pathway for such novel devices is complex and lengthy. Technical hurdles, such as ensuring reliable data transmission through body tissue and extending the device's battery life, also remain areas of active 360 Quadrant maps the Smart Pills companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Smart Pills quadrant. The top criteria for product footprint evaluation included Target Area (Small Intestine, Large Intestine, Esophagus, Stomach), Application (Capsule Endoscopy, Patient Monitoring, Targeted Drug Delivery), Disease Indication (Crohn's Disease, Occult Gastrointestinal Bleeding, Small Bowel Tumors, Celiac Disease, Other Disease Indications), End User (Hospitals, Diagnostic Centers, Outpatient Settings, Other End Users) Key Players: Major vendors in the Smart Pills market are Medtronic (US), Olympus Corporation (Japan), and CapsoVision, Inc. (US), IntroMedic (South Korea and Shangxian Minimal Invasive Inc. (China), Shenzhen Jifu Medical Technology Co., Ltd. (China), JINSHAN Science & Technology (China), and AnX Robotics (US), etectRx (US), Check-Cap (Israel), and BodyCap (France). The key strategies major vendors implement in the Smart Pills market are partnerships, collaborations, product launches, and product enhancements. Medtronic Medtronic plc is a global titan in healthcare technology, with a dominant market position across its Cardiovascular, Neuroscience, Medical Surgical, and Diabetes portfolios. The company is a leader in everything from pacemakers and insulin pumps to advanced surgical instruments. Strategically, Medtronic is focused on integrating AI, data analytics, and robotics - spearheaded by its HugoT surgical robot - into its offerings. Through active portfolio management and innovation in less-invasive technologies, the company aims to transform chronic disease management and surgical care worldwide, including in key growth markets like India. Olympus Corporation Olympus Corporation is the world's dominant leader in medical endoscopy, leveraging its legendary optical and digital expertise. The Japanese company provides a comprehensive range of endoscopes and therapeutic devices crucial for minimally invasive diagnosis and treatment in gastroenterology and other specialties. Strategically, Olympus has focused on becoming a pure-play medical technology company, divesting non-core assets. It is now heavily invested in integrating AI into its systems to enhance diagnostic accuracy and expanding its portfolio of therapeutic tools, solidifying its leadership in GI and beyond. CapsoVision, Inc CapsoVision, Inc. is an innovative medical device company specializing in gastrointestinal diagnostics through capsule endoscopy. Its flagship product, the CapsoCam Plus, sets itself apart with a unique 360-degree panoramic lateral camera, designed to provide a more comprehensive view of the small bowel. The company's strategy is to challenge established market players by leveraging this technological advantage and a simplified, data-recorder-free system for enhanced patient convenience. By focusing on improving diagnostic yield, CapsoVision aims to capture a growing share of the non-invasive GI imaging market. Key Topics Covered: 1 Introduction1.1 Market Definition1.2 Stakeholders2 Executive Summary3 Market Overview3.1 Introduction3.2 Market Dynamics3.2.1 Drivers3.2.1.1 Rising Demand for Non-Invasive Diagnostic Monitoring Devices3.2.1.2 Technological Advancements in Capsule Endoscopy3.2.1.3 Increasing Incidence of Colon Cancer3.2.2 Restraints3.2.2.1 High R&D Costs for Technological Developments and Advancements3.2.2.2 Low Accuracy and Reliability of Sensors and Cameras in Smart Pills3.2.3 Opportunities3.2.3.1 Innovations in Sensor Technologies and Wireless Communication3.2.3.2 Rising Need for Rapid Drug Delivery and Development3.2.4 Challenges3.2.4.1 Increased Patient Privacy and Data Security Concerns3.2.4.2 Shortage of Skilled Healthcare Professionals3.3 Industry Trends3.3.1 Advancements in Sensor Technologies3.3.2 Integration with Ai and Ml3.3.3 Integration with Wearable Devices3.4 Technology Analysis3.4.1 Key Technologies3.4.1.1 Wireless Communication Systems3.4.1.2 Sensor Technologies3.4.1.3 Self-Powered Ingestible Smart Pills3.4.1.4 Adaptive Frame Rate Technologies3.4.1.5 Imag3.4.1.6 Ai and Ml3.4.2 Complementary Technologies3.4.2.1 Robotic Technologies3.4.2.2 Data Analytics 3.4.3 Adjacent Technologies3.4.3.1 Iot3.4.3.2 Cloud Computing3.5 Trends/Disruptions Impacting Customer's Business3.6 Pipeline Analysis3.7 Porter's Five Forces Analysis3.8 Ecosystem Analysis3.9 Value Chain Analysis3.10 Patent Analysis3.10.1 Patent Publication Trends for Smart Pills3.10.2 Insights: Jurisdiction and Top Applicant Analysis3.10.3 List of Key Patents3.11 Key Conferences & Events, 2025-20263.12 Impact of Ai/Gen Ai on Smart Pills Market3.12.1 Key Use Cases3.12.2 Case Studies of Ai/Gen Ai Implementation3.12.2.1 Capsocam Sv-1 Versus Pillcam Sb3 to Detect Obscure Gastrointestinal Bleeding3.12.2.2 Aardex Group Partnered with Etectrx, Inc. to Track Medication-Taking Behaviors3.12.3 Impact of Ai/Gen Ai on Interconnected and Adjacent Ecosystems4 Competitive Landscape4.1 Introduction4.2 Key Player Strategies/Right to Win4.2.1 Overview of Strategies Adopted by Key Players in Smart Pills Market4.3 Revenue Analysis, 2019-20234.4 Market Share Analysis, 20234.5 Company Evaluation Matrix: Key Players, 20234.5.1 Stars4.5.2 Emerging Leaders4.5.3 Pervasive Players4.5.4 Participants4.5.5 Company Footprint: Key Players, 20234.5.5.1 Company Footprint4.5.5.2 Region Footprint4.5.5.3 Application Footprint4.5.5.4 Target Area Footprint4.5.5.5 Disease Indication Footprint4.5.5.6 End-User Footprint4.5.5.7 Region Footprint4.6 Company Evaluation Matrix: Startups/Smes, 20234.6.1 Progressive Companies4.6.2 Responsive Companies4.6.3 Dynamic Companies4.6.4 Starting Blocks4.6.5 Competitive Benchmarking: Startups/Smes, 20234.6.5.1 Detailed List of Key Startups/Sme Players4.6.5.2 Competitive Benchmarking of Key Startups/Sme Players4.7 Company Valuation & Financial Metrics4.7.1 Financial Metrics4.7.2 Company Valuation4.8 Brand/Product Comparison4.9 Competitive Scenario4.9.1 Product Launches, Approvals, and Enhancements4.9.2 Deals4.9.3 Other Developments5 Company Profiles Medtronic Olympus Corporation Capsovision, Inc. Intromedic Jinshan Science & Technology Anx Robotics Shenzhen Jifu Medical Technology Co., Ltd. Etectrx Bodycap Check-Cap Shangxian Minimal Invasive Inc. Veloce Corporation Biocam Endiatx Rf Co., Ltd. Celero Systems Biora Therapeutics, Inc. Innurvation Rani Therapeutics Motilis Medica Sa For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
CNN
3 days ago
- CNN
An Irish town makes all the world's Botox. Trump's trade deal could leave a mark
In ancient Celtic folklore, Tír na nÓg is the land of eternal youth, where time stands still and people don't age. Today, in the west of Ireland, they've come close to bottling it. Westport, a small coastal town in picturesque County Mayo, is the unlikely nerve center of the world's Botox supply. A facility operated by the Chicago-based pharmaceutical company AbbVie employs at least 1,300 local people and about 500 additional contractors – an economic backbone to a town of barely 7,000 people. Therapeutic Botox – used for conditions that include muscle spasticity, migraines, overactive bladders, certain eye conditions and excessive sweating – brought in $3.3 billion for AbbVie last year, with sales of cosmetic Botox, often used to smooth facial wrinkles, generating $2.72 billion. But last week, US President Donald Trump took a step toward his goal of bringing that multi-billion-dollar industry home, announcing 15% tariffs on all pharmaceutical exports from the European Union. It's a move that some fear could devastate towns like Westport, which has been transformed by the plant, from its opening by Allergan in 1977 to its acquisition and expansion in 2020 by AbbVie. Inside the sprawling 61-acre campus – a sleek industrial presence nestled below Croagh Patrick, one of the country's most storied pilgrimage sites – vials of Botox are processed and packaged in powder form, before export to some 70 countries, according to industry estimates. The US tops the list, accounting for 70% of total turnover at the Westport plant, which also makes eyecare products, according to the company's 2023 filings. Uncertainty about how the tariffs will impact the company has created anxiety for some in Westport, a community where the long-term benefits of the plant's presence cannot be overstated. It's embedded in the community, powering everything from infrastructure to sports teams and local charities. At AbbVie United Park, the home ground for the Westport United soccer club, where many of the company's workers and their families gather to train or cheer from the sidelines, locals said the tariffs could have a significant impact. No employee of AbbVie would speak on the record with CNN. But daycare center owner Anne-Marie, who chose not to give her surname for privacy reasons, said she had heard many parents who work at the plant – and leave their children in her care – voice anxiety about what could lie ahead. 'They are worried about their jobs, they just don't know how it's going to go. Is it going to affect them? Are they going to have a job this time next year? Is the company going to be able to keep going?' she said. 'And it'll have a knock-on effect for me, you know,' she said, adding: 'If they don't have a job, I won't have a job.' Brian Cusack, from the soccer club's development committee, was generally more upbeat about the future but believes 'a lot of change is going to happen, and maybe not change for the good.' 'Westport doesn't know what it's like without an American pharmaceutical treatment place. And I don't think we'd like to find out what it looks like without it,' said Cusack, whose 25-year-old daughter also works at the plant. Last month, after weeks of uncertainty, the US-EU trade deal was finally agreed upon. While some in Ireland and the wider bloc welcomed the agreement, other European leaders considered it an exercise in damage limitation. The calm after its announcement was to be short-lived. Singling out Ireland – the world's third-largest pharma exporter and home to pharma giants Johnson & Johnson and Pfizer – Trump said last Tuesday that upcoming tariffs on imported pharmaceuticals could reach 250% over the next 18 months. The threat comes as the US is currently conducting a Section 232 investigation into whether foreign drugs threaten national security, a process whose outcome could override the current US-EU trade deal. 'We want pharmaceuticals made in our country,' he said. But tariffs alone aren't likely to spark a mass move. While the idea of bringing pharmaceutical manufacturing back to the US resonates with Trump's base, putting it into practice is fraught with challenges. Experts say that while some drug production may shift to existing US facilities, full-scale reshoring is unlikely due to high costs, regulatory hurdles, supply chain challenges, and the long timelines for building or relocating high-tech plants – delays that could outlast any political changes. Anne-Marie suggested that the US president's moves could be purely political but said they have still managed to sow widespread concern. Still, she pointed to the resilience of the town – and Ireland – expressing the belief that Westport's industry will be able to outlast his administration. 'When he goes out of power, it's just gonna all change again – like it did the last time,' she said, referring to Trump's first term in office and noting that people's lives can't be dictated by what she characterized as the whims of one man. It's an attitude that is felt around the town. As traffic buzzed through the area, Mayo councillor Peter Flynn told CNN that while the tariffs have created 'a real headache,' people there are 'getting on with their lives.' Flynn, who worked at Allergan for nearly three decades, said that Trump's push to quickly bring manufacturing to the US was unrealistic. 'This kind of 'lift and shift' approach that Donald Trump is talking about – it's nonsensical,' he said. He argues that moving operations is extremely difficult, even domestically—let alone overseas—because of the gross logistical challenges it brings, let alone the skilled workers it requires, many of whom he says are now leaving the US 'at speed.' Plus, he added, 'anyone that's considering a location to move to – be it India or some of these other locations where a lot of graduates come from – are now taking the US off their map.' AbbVie, which declined to speak with CNN for this story, has not signaled any plans to move its Botox production hub. Addressing the tariffs in a recent public earnings call, AbbVie president Robert A. Michael said that the company was 'having constructive discussions with the administration on sectoral tariffs,' and noted that it will 'obviously continue to invest in the US.' On Tuesday, the company announced a $195 million investment in its Chicago manufacturing plant, in what it said was part of a broader commitment to invest more than $10 billion in US projects over the next decade. Other major drugmakers have also announced that they'll be scaling up American investment in response to the new tariffs. What these investments might mean for Ireland is unclear. But it's possibly not great news. Last year, pharmaceuticals made up €44 billion ($51.2 billion) of Ireland's total €72.6 billion ($84.5 billion) of exports to the US. Ahead of the tariff deal, Ireland appeared to proactively fast-track exports: €20 billion ($23 billion) worth of pharma goods were shipped to the US in the first two months of this year, according to official trade data. And while a trade war appears to have been averted for now, American consumers could be at the receiving end of soaring drug costs. ING analyst Diederik Stadig told CNN that a 15% tariff could increase US drug prices by 7% to 10%, adding up to $13 billion annually to health care costs. Consumers could shoulder the burden over time through higher health insurance premiums and increased drug prices at pharmacies. For products like cosmetic Botox, which isn't covered by US health insurance, the costs of procedures already considered a luxury could also rise, analysts say, putting a further strain on wallets. That's of concern to Westport hotelier Michael Lennon, whose US clientele are key to the tourism industry. Driving to pick up his American guests, who were horse riding at a nearby beach on Clew Bay, where he runs an equestrian trekking outfit, Lennon said he wasn't so worried about the Westport plant taking a hit. 'There's innovative thinking in every one of our businesses… and I think we'll adapt,' Lennon said, as his jeep rattled along the Wild Atlantic Way, a scenic route along the country's rugged coast. 'My worry would be that it (the increase in tariffs) could upset the American economy, and we need all these Americans coming to Ireland.' He then recalled a conversation he had with a Trump-supporting guest, who told him: 'What's good for America is good for Ireland.' Lennon said he hopes that's true. 'But I don't know. And neither does she,' he said. CNN's Tami Luhby contributed to this report.
